Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2013

01-02-2013 | Editorial

Lots of autoantibodies equal lupus?

Authors: Martin Aringer, Edward Vital

Published in: Arthritis Research & Therapy | Issue 1/2013

Login to get access

Abstract

Autoantibodies may be found years before an autoimmune disease becomes clinically apparent. For systemic lupus erythematosus (SLE), those to RNA-binding proteins, to phospholipids, and to double-stranded DNA, in particular, have been found in sera of SLE patients years before the diagnosis was made. New data now show in an unbiased way that, in patients with early SLE, no single antibody class or specificity is associated with progression to SLE. Rather, an increasing number of autoantibody specificities, such as to thyroid antigens, was observed in patients progressing. This points to more generalized B cell autoreactivity during progression to SLE, underlying lupus disease manifestations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Olsen NJ, Li Q-Z, Quan J, Wang L, Mutwally A, Karp DR: Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012, 14: R174-10.1186/ar3927.PubMedCentralCrossRefPubMed Olsen NJ, Li Q-Z, Quan J, Wang L, Mutwally A, Karp DR: Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012, 14: R174-10.1186/ar3927.PubMedCentralCrossRefPubMed
2.
go back to reference Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999, 40: 167-170. 10.1016/S0190-9622(99)70183-0.CrossRefPubMed Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999, 40: 167-170. 10.1016/S0190-9622(99)70183-0.CrossRefPubMed
3.
go back to reference Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA: The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med. 2003, 197: 1501-1510. 10.1084/jem.20022031.PubMedCentralCrossRefPubMed Li N, Aoki V, Hans-Filho G, Rivitti EA, Diaz LA: The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med. 2003, 197: 1501-1510. 10.1084/jem.20022031.PubMedCentralCrossRefPubMed
4.
go back to reference Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed
5.
go back to reference Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans BA, van Schaardenburg D: Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010, 69: 490-494. 10.1136/ard.2008.105759.CrossRefPubMed Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, Tak PP, van de Stadt RJ, van der Laken CJ, Dijkmans BA, van Schaardenburg D: Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010, 69: 490-494. 10.1136/ard.2008.105759.CrossRefPubMed
6.
go back to reference Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533. 10.1056/NEJMoa021933.CrossRefPubMed Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533. 10.1056/NEJMoa021933.CrossRefPubMed
7.
go back to reference Cappelli S, Bellando RS, Martinovic D, Tamas MM, Pasalic K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radic M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirjak L, Damjanov N, et al: "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2011, 41: 589-598.CrossRefPubMed Cappelli S, Bellando RS, Martinovic D, Tamas MM, Pasalic K, Allanore Y, Mosca M, Talarico R, Opris D, Kiss CG, Tausche AK, Cardarelli S, Riccieri V, Koneva O, Cuomo G, Becker MO, Sulli A, Guiducci S, Radic M, Bombardieri S, Aringer M, Cozzi F, Valesini G, Ananyeva L, Valentini G, Riemekasten G, Cutolo M, Ionescu R, Czirjak L, Damjanov N, et al: "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2011, 41: 589-598.CrossRefPubMed
8.
go back to reference Li QZ, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, Mohan C, Wakeland EK, Olsen NJ: Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007, 147: 60-70.PubMedCentralPubMed Li QZ, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, Mohan C, Wakeland EK, Olsen NJ: Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007, 147: 60-70.PubMedCentralPubMed
9.
go back to reference Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 2008, 358: 929-939. 10.1056/NEJMra071297.CrossRefPubMed Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 2008, 358: 929-939. 10.1056/NEJMra071297.CrossRefPubMed
10.
go back to reference Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, Dorner T: HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2010, 69: 305-308. 10.1136/ard.2008.096495.CrossRefPubMed Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, Dorner T: HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2010, 69: 305-308. 10.1136/ard.2008.096495.CrossRefPubMed
11.
go back to reference Sestak AL, Furnrohr BG, Harley JB, Merrill JT, Namjou B: The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011, 70 (Suppl 1): i37-i43. 10.1136/ard.2010.138057.CrossRefPubMed Sestak AL, Furnrohr BG, Harley JB, Merrill JT, Namjou B: The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011, 70 (Suppl 1): i37-i43. 10.1136/ard.2010.138057.CrossRefPubMed
Metadata
Title
Lots of autoantibodies equal lupus?
Authors
Martin Aringer
Edward Vital
Publication date
01-02-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4126

Other articles of this Issue 1/2013

Arthritis Research & Therapy 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.